Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,accountsPayable,otherCurrentAssets,otherLiab,shortTermInvestments,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,netBorrowings,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,preMarketChange,preMarketChangePercent,preMarketTime,preMarketPrice,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,dividendDate,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,IDRA,42304000.0,50033300,2975000,,115738000,,115738000,3156000,-3896000,-10027000,-10027000,,-3000,,,,0,0,10027000,3896000,125765000,,115738000,109606000,760072000.0,5704000.0,42304000.0,217000.0,48008000.0,46000.0,-717814000.0,70000.0,44541000.0,4996000.0,920000.0,47018000.0,185000.0,,,,4500000.0,-1879000.0,4500000.0,16403000.0,1153000.0,16621000.0,11312000.0,-9591000.0,6000.0,-218000.0,-124609000.0,,,42022000.0,en-US,US,EQUITY,True,Delayed Quote,USD,4,NCM,1.08,1630526402,-0.00999999,1.07,1.11,1.07,305344,0,"Idera Pharmaceuticals, Inc.",PRE,us_market,-0.00999999,-0.925925,1630571688,1.07,-0.91743034,1.07 - 1.11,1.09,0.0,0.0,32,14,finmb_29643,NasdaqCM,"Idera Pharmaceuticals, Inc.",USD,2300606,536942,0.110000014,0.113402076,0.97 - 6.14,-5.06,-0.82410425,1532908800,0.97,6.14,1619693940,1627901940,1628251200,0.027453197,1.7628986,-0.6828985,-0.38737255,-1.8947369,-3.555,-0.57,-0.68,-1.5882354,0.909,1.0511428,0.028857231,54035968,1.1881189,15,America/New_York,EDT,-14400000,False,False,1.82,,,6.14,0.97,1.0511,1.7629,2.3M,536.94k,50.03M,,38.65M,22.62%,19.73%,3.7M,3.51,9.40%,7.40%,3.7M,,,,,,0.00%,"Jul 29, 2018",,1:8,"Jul 29, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-49.31%,-27.23%,,,,-16.71M,-33.52M,-11.23M,-3.5550,"1,212.70%",44.54M,0.89,1.12M,2.65,9.41,0.91,-32.62M,-46.17M,Value,19341,Healthcare,32,5,8,"Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.",Exton,484 348 1600,PA,8,1609372800,1622505600,2,United States,http://www.iderapharma.com,86400,5,505 Eagleview Boulevard,484 348 1670,Biotechnology,Suite 212
t-1,IDRA,-91172000.0,50033300,1790000,,-76701000,,-76701000,2923000,-3327000,-8040000,-8040000,,-3000,,,,0,0,8040000,3327000,-68661000,,-76701000,-76701000,742342000.0,133571000.0,-91172000.0,,42399000.0,38000.0,-833552000.0,70000.0,33229000.0,7027000.0,974000.0,41355000.0,329000.0,2500000.0,125786000.0,4499000.0,2151000.0,-238000.0,2150000.0,16327000.0,-714000.0,16544000.0,10897000.0,-7580000.0,9000.0,-218000.0,70064000.0,-217000.0,-1000.0,34328000.0,en-US,US,EQUITY,True,Delayed Quote,USD,4,NCM,1.08,1630526402,-0.00999999,1.07,1.11,1.07,305344,0,"Idera Pharmaceuticals, Inc.",PRE,us_market,-0.00999999,-0.925925,1630571688,1.07,-0.91743034,1.07 - 1.11,1.09,0.0,0.0,32,14,finmb_29643,NasdaqCM,"Idera Pharmaceuticals, Inc.",USD,2300606,536942,0.110000014,0.113402076,0.97 - 6.14,-5.06,-0.82410425,1532908800,0.97,6.14,1619693940,1627901940,1628251200,0.027453197,1.7628986,-0.6828985,-0.38737255,-1.8947369,-3.555,-0.57,-0.68,-1.5882354,0.909,1.0511428,0.028857231,54035968,1.1881189,15,America/New_York,EDT,-14400000,False,False,1.82,,,6.14,0.97,1.0511,1.7629,2.3M,536.94k,50.03M,,38.65M,22.62%,19.73%,3.7M,3.51,9.40%,7.40%,3.7M,,,,,,0.00%,"Jul 29, 2018",,1:8,"Jul 29, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-49.31%,-27.23%,,,,-16.71M,-33.52M,-11.23M,-3.5550,"1,212.70%",44.54M,0.89,1.12M,2.65,9.41,0.91,-32.62M,-46.17M,Value,19341,Healthcare,32,5,8,"Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.",Exton,484 348 1600,PA,8,1609372800,1622505600,2,United States,http://www.iderapharma.com,86400,5,505 Eagleview Boulevard,484 348 1670,Biotechnology,Suite 212
t-2,IDRA,-32435000.0,50033300,1948000,,-20552000,,-20552000,2718000,-2818000,-7484000,-7484000,,-3000,,,,0,0,7484000,2818000,-13068000,,-20552000,-20552000,724381000.0,64773000.0,-32435000.0,,32338000.0,35000.0,-756851000.0,70000.0,22332000.0,6805000.0,1029000.0,31239000.0,310000.0,,57160000.0,6647000.0,-3444000.0,-816000.0,-3444000.0,5058000.0,398000.0,5058000.0,-5478000.0,-7092000.0,11000.0,-218000.0,13867000.0,-217000.0,-1000.0,24434000.0,en-US,US,EQUITY,True,Delayed Quote,USD,4,NCM,1.08,1630526402,-0.00999999,1.07,1.11,1.07,305344,0,"Idera Pharmaceuticals, Inc.",PRE,us_market,-0.00999999,-0.925925,1630571688,1.07,-0.91743034,1.07 - 1.11,1.09,0.0,0.0,32,14,finmb_29643,NasdaqCM,"Idera Pharmaceuticals, Inc.",USD,2300606,536942,0.110000014,0.113402076,0.97 - 6.14,-5.06,-0.82410425,1532908800,0.97,6.14,1619693940,1627901940,1628251200,0.027453197,1.7628986,-0.6828985,-0.38737255,-1.8947369,-3.555,-0.57,-0.68,-1.5882354,0.909,1.0511428,0.028857231,54035968,1.1881189,15,America/New_York,EDT,-14400000,False,False,1.82,,,6.14,0.97,1.0511,1.7629,2.3M,536.94k,50.03M,,38.65M,22.62%,19.73%,3.7M,3.51,9.40%,7.40%,3.7M,,,,,,0.00%,"Jul 29, 2018",,1:8,"Jul 29, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-49.31%,-27.23%,,,,-16.71M,-33.52M,-11.23M,-3.5550,"1,212.70%",44.54M,0.89,1.12M,2.65,9.41,0.91,-32.62M,-46.17M,Value,19341,Healthcare,32,5,8,"Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.",Exton,484 348 1600,PA,8,1609372800,1622505600,2,United States,http://www.iderapharma.com,86400,5,505 Eagleview Boulevard,484 348 1670,Biotechnology,Suite 212
t-3,IDRA,-17691000.0,50033300,1948000,,-24226000,,-24226000,2632000,-5379000,-8011000,-8011000,,-3000,,,,0,0,8011000,5379000,-16215000,,-24226000,-24226000,718574000.0,52476000.0,-17691000.0,16000.0,34785000.0,34000.0,-736299000.0,70000.0,27810000.0,7534000.0,1028000.0,33687000.0,345000.0,,44127000.0,3196000.0,2400000.0,-723000.0,2400000.0,5853000.0,-490000.0,5853000.0,-99000.0,-8352000.0,17000.0,-218000.0,17070000.0,-217000.0,-1000.0,26153000.0,en-US,US,EQUITY,True,Delayed Quote,USD,4,NCM,1.08,1630526402,-0.00999999,1.07,1.11,1.07,305344,0,"Idera Pharmaceuticals, Inc.",PRE,us_market,-0.00999999,-0.925925,1630571688,1.07,-0.91743034,1.07 - 1.11,1.09,0.0,0.0,32,14,finmb_29643,NasdaqCM,"Idera Pharmaceuticals, Inc.",USD,2300606,536942,0.110000014,0.113402076,0.97 - 6.14,-5.06,-0.82410425,1532908800,0.97,6.14,1619693940,1627901940,1628251200,0.027453197,1.7628986,-0.6828985,-0.38737255,-1.8947369,-3.555,-0.57,-0.68,-1.5882354,0.909,1.0511428,0.028857231,54035968,1.1881189,15,America/New_York,EDT,-14400000,False,False,1.82,,,6.14,0.97,1.0511,1.7629,2.3M,536.94k,50.03M,,38.65M,22.62%,19.73%,3.7M,3.51,9.40%,7.40%,3.7M,,,,,,0.00%,"Jul 29, 2018",,1:8,"Jul 29, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-49.31%,-27.23%,,,,-16.71M,-33.52M,-11.23M,-3.5550,"1,212.70%",44.54M,0.89,1.12M,2.65,9.41,0.91,-32.62M,-46.17M,Value,19341,Healthcare,32,5,8,"Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.",Exton,484 348 1600,PA,8,1609372800,1622505600,2,United States,http://www.iderapharma.com,86400,5,505 Eagleview Boulevard,484 348 1670,Biotechnology,Suite 212
